Latest Us Department Of Defense News

A handful of small caps ripped higher, but plenty still slipped even after good news. This week’s biggest moves came from a platform partnership win, a reinstated stock, and a cash settlement that removed a long-running dispute.

Bio-Gene Technology Limited reports strong progress in advancing its Flavocide® and Qcide® insecticidal platforms, backed by US Department of Defense funding and key organic certification in the US.

xReality Group Limited has reported its strongest quarter yet, with record cash receipts and a doubling sales pipeline, underpinned by major US defence contracts and expanded production capacity.

A takeover premium blew the doors off the Materials board this week, while one discounted equity raise did the opposite. Uranium names kept climbing on real production progress, and rare earths stayed in favour as governments and buyers circle supply.

A takeover offer lit up small caps, while one high-growth software name slid hard despite strong sector news. Resources dominated the winners list, but investors still punished dilution and discounted fundraisings.

Metal Powder Works reported a stellar December quarter with a threefold increase in CP-Ti orders, expansion into precious metals, and strategic contracts that position it strongly in defence and advanced manufacturing markets.

Nova Minerals’ 2025 drilling at the Korbel Gold Deposit in Alaska reveals a near-surface higher-grade core, supporting a pilot starter pit and promising cost efficiencies through ore sorting.

Bio-Gene Technology reports promising progress on its US Department of Defense-funded insecticide projects, with early mosquito mortality evidence from its Flavocide wearable device and pending launch of its Qcide indoor spray program.

6K Additive, Inc. launches a fully underwritten A$48 million IPO on the ASX, aiming to scale its innovative scrap-based metal powder production for additive manufacturing. The capital raise supports a major capacity expansion backed by a US Department of Defense grant.

xReality Group Limited reported a robust 36% revenue increase in FY25, driven by rapid expansion of its Operator XR platform and strategic balance sheet improvements. The company’s optimistic outlook for FY26 is underpinned by new contracts, AI investments, and international distributor expansion.

Bio-Gene Technology reports significant progress in developing its bio-insecticides Flavocide and Qcide, including new efficacy data and organic certification, positioning the company for growth amid rising global demand for safer pest control.

ReNerve Limited’s innovative NervAlign® Nerve Cuff has secured approval for use across the US Department of Defense and Veterans Affairs healthcare systems, marking a major milestone for the Australian medtech company.